Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11434419 | 0.89 | MGAM (0.46) | MGAMGAASIMGAM2CYP2C19 | |
| SCHEMBL27854343 | 0.89 | MGAM (0.36) | MGAMGAASIMGAM2CYP2C19 | |
| SCHEMBL24214077 | 0.84 | ADRA2A (0.40) | CYP2C19L3MBTL1ADRA2AADRA1AMAPT | |
| SCHEMBL27436791 | 0.83 | MGAM (0.32) | MGAMGAASIMGAM2CYP2C19 | |
| SCHEMBL6792231 | 0.83 | NAAA (0.50) | GAACYP2C19L3MBTL1BLMNAAA | |
| SCHEMBL29021423 | 0.83 | MIF (0.36) | CYP2C19L3MBTL1ADRA2AADRA1AMAPT | |
| SCHEMBL10854964 | 0.83 | CYP2C19 (0.56) | CYP2C19L3MBTL1ADRA2AADRA1AFAAH | |
| SCHEMBL24630436 | 0.82 | TDP1 (0.34) | GAACYP2C19L3MBTL1EGFR | |
| SCHEMBL6791519 | 0.81 | CYP2C19 (0.34) | CYP2C19L3MBTL1ADRA2AADRA1AMAPT | |
| SCHEMBL5500580 | 0.81 | DGKA (0.48) | ADRA2AADRA1AMAPTBLMDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025047490-A1 | GAS SEPARATION MEMBRANE AND METHOD FOR PRODUCING GAS SEPARATION MEMBRANE | 株式会社ダイセル | 2025-03-06 | — | — | WO | disclosed |
| WO-2025028075-A1 | TWO-PACK TYPE RESIN COMPOSITION | 株式会社日本触媒 | 2025-02-06 | — | — | WO | disclosed |
| CN-119278199-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-116323837-B | Polyurethane curing agent and application thereof | 旭化成株式会社 | 2024-10-25 | — | — | CN | disclosed |
| CN-115916777-B | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115335369-B | GEM-disubstituted piperidine melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118271261-A | Dicarbonyl compound containing cyclobutane segment and synthesis method thereof | 中国科学技术大学 | 2024-07-02 | — | — | CN | disclosed |
| EP-3771720-B1 | BLOCKED POLYISOCYANATE COMPOSITION, RESIN COMPOSITION, RESIN FILM AND LAMINATE | ASAHI CHEMICAL IND (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-5229243-A | Addition polymer core, polyurethane or polythiourethane shell | KAO CORPORATION (JP) | 1993-07-20 | — | — | US | disclosed |
| EP-0501673-A1 | Encapsulated toner for heat pressure fixing | Kao Corporation (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4596883-A | Herbicidally active substituted diphenyl ethers | PPG INDUSTRIES, INC. (US) | 1986-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | MGAM 312/4885GAA 1264/4885SI 195/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | MGAM 575/4885GAA 887/4885SI 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.